▶Table 1 (Continuation)MAPS I MAPS

▶Table 1 (Continuation)MAPS I MAPS II (in bold if modified)20 H. pylori eradication is recommended for patients with previousneoplasia after endoscopic or surgical therapy22 H. pylori eradication is recommended for patients with gastricneoplasia after endoscopic therapy (high quality evidence, strongrecommendation)21 Currently, the use of cyclo-oxgenase-2 (COX-2) inhibitors cannot besupported as an approach to decrease the risk of progression of gastricprecancerous lesions23 Even though cyclo-oxygenase (COX)-1 or COX-2 inhibitors mayslow progression of gastric precancerous conditions, they cannot berecommended specifically for this purpose (low quality evidence,weak recommendation)22 The use of dietary supplementation with antioxidants (ascorbic acidand betacarotene) cannot be supported as a therapy to reduce theprevalence of atrophy or intestinal metaplasia24 Low dose daily aspirin may be considered for prevention of various cancers, including gastric cancer, in selected patients (moderatequality evidence, weak recommendation)Cost-effectiveness23 After endoscopic resection of early gastric cancer, H. pylori eradication is cost-effective25 In intermediate to high risk regions, identification and surveillance of patients with precancerous gastric conditions is costeffective (moderate quality evidence)24 Currently available evidence does not allow an accurate estimationof the cost-effectiveness of surveillance for premalignant gastric conditions worldwideRECOMMENDATION5 Patients with an endoscopically visible lesion harboringlow or high grade dysplasia or carcinoma should undergostaging and treatment.High quality evidence, strong recommendation (94 %agree [94 % strongly or moderately agree]).Pimentel-Nunes Pedro et al. MAPS II … EndoscopyGuidelinehttp://guide.medlive.cn/This document was downloaded for personal use only. Unauthorized distribut